This article is more than 5 years old. Information may no longer be current.
Study of microplasmin enzyme under way
NUREMBERG, Germany — An enzyme that may improve the success of vitrectomy surgery is undergoing preclinical testing, according to a speaker here.
Anselm Kampik, MD, said the enzyme, called microplasmin, is currently undergoing tests to determine the most effective dose and timing for its use.
“We expect that one year from now we will have a dose-ranging curve, and then we can do clinical tests,” Dr. Kampik told attendees here at the Congress of German Ophthalmic Surgeons.
According to Dr. Kampik, microplasmin induces vitreous detachment in a dose-dependent fashion.
“Complete vitreoretinal separation is possible without any damage to the retina,” he said.
Earlier iterations of the enzyme plasmin had been successful in separating the vitreous but not at the vitreous base, he said.